SCHEMBL177558

SCHEMBL177558

CCCC(=O)NS(=O)(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 3/20 0.50
HDAC1 Q13547 3/20 0.50
HDAC2 Q92769 3/20 0.50
HDAC8 Q9BY41 3/20 0.50
HDAC6 Q9UBN7 1/20 0.50
FNTA P49354 1/20 0.48
FNTB P49356 1/20 0.48
CTSD P07339 1/20 0.48
CASP2 P42575 1/20 0.45
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 2/20 0.39
CA12 O43570 1/20 0.39
FFAR3 O14843 2/20 0.38
TP53 P04637 1/20 0.38
NSD2 O96028 1/20 0.36
TTR P02766 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7527834 0.98 HDAC3 (0.48) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL8087887 0.98 HDAC3 (0.48) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL3477319 0.86 FNTA (0.46) FNTAFNTBCASP2CES2CES1
SCHEMBL7180177 0.84 HSP90AA1 (0.54) FNTAFNTBCASP2CES2CES1
SCHEMBL11649466 0.82 HSP90AA1 (0.57) CASP2CES2CES1TSHREPHX2
SCHEMBL21060856 0.82 HSP90AA1 (0.57) CASP2CES2CES1TSHREPHX2
SCHEMBL7184916 0.82 HSP90AA1 (0.57) CASP2CES2CES1TSHREPHX2
SCHEMBL7185340 0.82 HSP90AA1 (0.57) CASP2CES2CES1TSHREPHX2
SCHEMBL28194397 0.82 HSP90AA1 (0.52) FNTAFNTBCASP2CES2CES1
SCHEMBL7558419 0.82 HDAC3 (0.52) HDAC3HDAC1HDAC2HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6583130-B1 Substituted with acyl, oxycarbonyl, aminocarbonyl, sulfonyl, or aminosulfonyl; inhibit steroid sulfatase, do not exhibit any estrogenic effect and will not yield any estrogenic products on hydrolysis; treatment of estrogen-dependent tumors SCHERING AG (DE) 2003-06-24 US claimed
EP-2386538-B1 N-(1-HYDROXYETHYL)CARBOXAMIDE COMPOUND AND PROCESS FOR PRODUCING SAME SHOWA DENKO KK (JP) 2015-07-29 EP disclosed
US-8697912-B2 N-(1-hydroxyethyl) carboxamide compound and process for producing same SHOWA DENKO K.K. (JP) 2014-04-15 US disclosed
US-8383745-B2 Method for producing N-methyl-N-vinylacetamide having improved stability and polymerizability SHOWA DENKO K.K. (JP) 2013-02-26 US disclosed
US-20110294974-A1 N-(1-HYDROXYETHYL ) CARBOXAMIDE COMPOUND AND PROCESS FOR PRODUCING SAME SHOWA DENKO K.K. (JP) 2011-12-01 US disclosed
EP-2386538-A1 N-(1-HYDROXYETHYL)CARBOXAMIDE COMPOUND AND PROCESS FOR PRODUCING SAME Showa Denko K.K. (JP) 2011-11-16 EP disclosed
US-20100280204-A1 METHOD FOR PRODUCING N-METHYL-N-VINYLACETAMIDE HAVING IMPROVED STABILITY AND POLYMERIZABILITY SHOWA DENKO K.K. (JP) 2010-11-04 US disclosed
EP-2239250-A1 METHOD FOR PRODUCING N-METHYL-N-VINYLACETAMIDE HAVING IMPROVED STABILITY AND POLYMERIZABILITY Showa Denko K.K. (JP) 2010-10-13 EP disclosed
EP-1291397-B1 INK SET FOR INK-JET RECORDING SEIKO EPSON CORP (JP) 2006-12-27 EP disclosed
US-6767090-B2 Ink set for ink-jet recording SEIKO EPSON CORPORATION (JP) 2004-07-27 US disclosed
WO-1998039316-A1 N-HYDROXY 4-SULFONYL BUTANAMIDE COMPOUNDS MONSANTO COMPANY (US) 1998-09-11 WO disclosed
US-5789619-A USED AS COAGULANTS, LIQUID ABSORBENTS, THICKENERS SHOWA DENKO KABUSHIKI KAISHA (JP) 1998-08-04 US disclosed
EP-0812311-A1 HIGHLY POLYMERIZABLE N-VINYLCARBOXYLIC ACID AMIDE AND PRODUCTION PROCESS THEREOF SHOWA DENKO KABUSHIKI KAISHA (JP) 1997-12-17 EP disclosed
EP-0799820-A1 Process producing n-(1-alkoxyethyl)carboxylic amides SHOWA DENKO KABUSHIKI KAISHA (JP) 1997-10-08 EP disclosed
WO-1997024315-A1 HIGHLY POLYMERIZABLE N-VINYLCARBOXYLIC ACID AMIDE AND PRODUCTION PROCESS THEREOF SHOWA DENKO K.K. (JP) 1997-07-10 WO disclosed
EP-0510246-B1 Use of fine particulate crosslinked type n-vinylamide resin microgel SHOWA DENKO KK (JP) 1996-09-25 EP disclosed
US-5338815-A Used in thickeners, dispersion stabilizers and lubricants SHOWA DENKO K.K. (JP) 1994-08-16 US disclosed
US-5280095-A N-vinylcarboxylic acid amine resin SHOWA DENKO K.K. (JP) 1994-01-18 US disclosed
EP-0510246-A1 Use of fine particulate crosslinked type n-vinylamide resin microgel SHOWA DENKO KABUSHIKI KAISHA (JP) 1992-10-28 EP disclosed
US-3957860-A SULFAMIC ACID CIBA-GEIGY AG (CH) 1976-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294974-A1 N-(1-HYDROXYETHYL ) CARBOXAMIDE COMPOUND AND PROCESS FOR PRODUCING SAME ADH1A, ADH1C, CNKSR1 HDAC3 150/4885HDAC1 20/4885HDAC2 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.